Skip to main content
. Author manuscript; available in PMC: 2018 Nov 19.
Published in final edited form as: Clin Cancer Res. 2016 Jun 22;23(1):88–96. doi: 10.1158/1078-0432.CCR-16-0825

Table 2. Mutations identified in matched FFPE, cfDNA and individual CTCs.

AF; Allele frequency; -----; no mutation detected; NC, no coverage at this amplicon. ------/NC; PIK3CA mutation not detected/No coverage at ESR1 mutation site. Shown are COSMIC mutations detected in individual CTCs (C1, 2), CTC pools (Cpool) matched plasma cfDNA and two regions of primary tumor. Patient CTCM167 had two serial samples for both CTCs and plasma cfDNA. All data are summarized in Supplementary Tables 10-13.

Sample ID Receptor status CTC cfDNA (AF) Primary tumor region 1 (AF) Primary tumor region 2 (AF)
CTCM155 ER+/PR+/HER2- C1 PIK3CA p.E545K; ESR1 p.E380Q PIK3CA p.E545K (23.7%); ESR1 p.E380Q (3.9%) PIK3CA p.E545K (67.8%) PIK3CA p.E545K (72.4%)
C2 PIK3CA p.E545K; ESR1 p.E380Q
C3 PIK3CA p.E545K; ESR1 p.E380Q
C4 PIK3CA p.E545K; ESR1 p.E380Q
C5 PIK3CA p.E545K
Cpool PIK3CA p.E545K; ESR1 p.E380Q
CTCM138 ER+/PR+/HER2- C1 -----/NC PIK3CA p.H1047R (31%); ESR1 p.E380Q (23.8%); TP53 p.R175H (0.3%); ESR1 Y537C (0.43%) PIK3CA p.H1047R (14.2%); TP53 p.R175H (1.9%) PIK3CA p.H1047R (36%); TP53 p.R175H (0.99%)
C2 PIK3CA p.H1047R; ESR1 p.E380Q
C3 PIK3CA p.H1047R; ESR1 p.E380Q
C4 -----
C5 -----
Cpool PIK3CA p.H1047R; ESR1 p.E380Q
CTCM105 ER-/PR-/HER2- C1 KRAS p.G12D KRAS p.G12D (3.8%); TP53 p.P278R (2.3%) ----- -----
C2 KRAS p.G12D
C3 KRAS p.G12D
C4 -----
C5 KRAS p.G12D
C6 KRAS p.G12D
C7 NC
C8 KRAS p.G12D
C9 -----
C10 KRAS p.G12D
C11 NC
Cpool KRAS p.G12D
CTCM292 ER+/PR+/HER2- C1 PIK3CA p.E545K; ESR1 p.D538G PIK3CA p.E545K (0.17%); ESR1 p.D538G (0.27%) None available None available
C2 PIK3CA p.E545K; ESR1 p.D538G
CTCM167.1 ER+/PR+/HER2- C1 ----- ----- ----- -----
C2 -----
C3 -----
C4 -----
C5 -----
Cpool -----
CTCM167.2 C1 ----- ----- ----- -----
C2 -----
C3 -----
C4 -----
C5 -----
C6 -----
C7 -----
C8 -----
C9 -----
C10 -----
C11 -----
C12 -----
Cpool -----